Analgesic efficacy of controlled-release oxycodone in postoperative pain. 1996

A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
Department of Medicine, New York University Medical Center, Analgesic Development Ltd., New York 10021-3522, USA.

The efficacy and safety of graded doses (10, 20, and 30 mg) of controlled-release (CR) oxycodone was compared with that of immediate-release (IR) oxycodone (15 mg), immediate-release oxycodone 10 mg in combination with acetaminophen 650 mg (APAP), and placebo in a single-dose, double-blind, randomized, parallel-group study. The participants, 182 inpatients experiencing moderate to severe pain after abdominal or gynecologic surgery, provided hourly ratings of pain intensity and relief for 12 hours after administration. All active treatments were significantly superior to placebo for many hourly measurements and for the sum of pain intensity differences (SPID) and total pain relief (TOTPAR). A dose response was found among the three levels of CR oxycodone for pain relief and peak pain intensity difference (PID), with the 20- and 30-mg doses being significantly better than the 10-mg dose. For all active treatments, peak PID and peak pain relief occurred approximately 2 to 4 hours after administration. The median time to onset of relief was 32 minutes for oxycodone plus APAP, 41 minutes for IR oxycodone, and 46 minutes for CR oxycodone 30 mg. Duration of pain relief showed that the 10-, 20-, and 30-mg doses of CR oxycodone had durations of action of 10 to 12 hours compared with IR oxycodone and oxycodone plus APAP (both approximately 7 hours). Typical adverse events, particularly somnolence, occurred in all active treatment groups. Treatment with CR oxycodone was safe and effective in this study, and its characteristics will be beneficial in the treatment of pain.

UI MeSH Term Description Entries
D008297 Male Males
D010098 Oxycodone A semisynthetic derivative of CODEINE. Dihydrohydroxycodeinone,Oxiconum,Oxycodeinon,Dihydrone,Dinarkon,Eucodal,Oxycodone Hydrochloride,Oxycone,Oxycontin,Pancodine,Theocodin
D010149 Pain, Postoperative Pain during the period after surgery. Acute Post-operative Pain,Acute Postoperative Pain,Chronic Post-operative Pain,Chronic Post-surgical Pain,Chronic Postoperative Pain,Chronic Postsurgical Pain,Pain, Post-operative,Persistent Postsurgical Pain,Post-operative Pain,Post-operative Pain, Acute,Post-operative Pain, Chronic,Post-surgical Pain,Postoperative Pain, Acute,Postoperative Pain, Chronic,Postsurgical Pain,Postoperative Pain,Acute Post operative Pain,Chronic Post operative Pain,Chronic Post surgical Pain,Chronic Postsurgical Pains,Pain, Acute Post-operative,Pain, Acute Postoperative,Pain, Chronic Post-operative,Pain, Chronic Post-surgical,Pain, Chronic Postoperative,Pain, Chronic Postsurgical,Pain, Persistent Postsurgical,Pain, Post operative,Pain, Post-surgical,Pain, Postsurgical,Post operative Pain,Post operative Pain, Acute,Post operative Pain, Chronic,Post surgical Pain,Post-operative Pains,Post-surgical Pain, Chronic,Postsurgical Pain, Chronic,Postsurgical Pain, Persistent
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000082 Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. Acetamidophenol,Hydroxyacetanilide,Paracetamol,APAP,Acamol,Acephen,Acetaco,Acetominophen,Algotropyl,Anacin-3,Datril,N-(4-Hydroxyphenyl)acetanilide,N-Acetyl-p-aminophenol,Panadol,Tylenol,p-Acetamidophenol,p-Hydroxyacetanilide,Anacin 3,Anacin3

Related Publications

A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
April 2004, Journal of pain and symptom management,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
February 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
August 1999, European journal of clinical pharmacology,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
January 2008, American journal of therapeutics,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
May 1998, Acta anaesthesiologica Scandinavica,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
March 2003, Pain medicine (Malden, Mass.),
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
March 2003, Journal of clinical pharmacology,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
January 1994, Advances in therapy,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
September 2017, Chinese journal of cancer,
A Sunshine, and N Z Olson, and A Colon, and J Rivera, and R F Kaiko, and R D Fitzmartin, and R F Reder, and P D Goldenheim
September 2006, Therapeutics and clinical risk management,
Copied contents to your clipboard!